Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 14/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 3/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 3/20 | 0.50 |
| ▸ | RXRA | P19793 | 8/20 | 0.47 |
| ▸ | RXRB | P28702 | 8/20 | 0.47 |
| ▸ | RXRG | P48443 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | C5 | P01031 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762311 | 0.77 | NR4A2 (0.62) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11536916 | 0.75 | NR4A2 (0.60) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL330227 | 0.75 | NR4A2 (1.00) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2744315 | 0.75 | NR4A2 (0.60) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11450560 | 0.75 | NR4A2 (0.65) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6025571 | 0.75 | NR4A2 (0.60) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2091239 | 0.75 | MAPK13 (0.83) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10402722 | 0.75 | NR4A2 (0.60) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11750949 | 0.75 | NR4A2 (0.60) | NR4A2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7486524 | 0.75 | NR4A2 (0.59) | NR4A2MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-4778799-A | ANALGESIC, ANTIPYRETIC, ANTIINFLAMMATORY AGENT | TIBES ULRICH (DE) | 1988-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | NR4A2 3/4885MAPK13 3280/4885MAPK12 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.